Eli Lilly and Company (NYSE:LLY) Shares Sold by Community Bank & Trust Waco Texas

Community Bank & Trust Waco Texas lowered its stake in Eli Lilly and Company (NYSE:LLY) by 3.1% during the third quarter, Holdings Channel.com reports. The institutional investor owned 620 shares of the company’s stock after selling 20 shares during the period. Community Bank & Trust Waco Texas’ holdings in Eli Lilly and Company were worth $549,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of LLY. China Universal Asset Management Co. Ltd. increased its holdings in Eli Lilly and Company by 19.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after purchasing an additional 1,620 shares in the last quarter. William Blair Investment Management LLC bought a new position in Eli Lilly and Company in the first quarter worth about $1,540,000. D Orazio & Associates Inc. raised its holdings in shares of Eli Lilly and Company by 2.5% during the first quarter. D Orazio & Associates Inc. now owns 1,936 shares of the company’s stock valued at $1,506,000 after buying an additional 48 shares during the last quarter. TBH Global Asset Management LLC increased its stake in shares of Eli Lilly and Company by 10.9% during the first quarter. TBH Global Asset Management LLC now owns 2,021 shares of the company’s stock valued at $1,572,000 after acquiring an additional 199 shares during the period. Finally, Kingsview Wealth Management LLC increased its stake in shares of Eli Lilly and Company by 2.9% during the first quarter. Kingsview Wealth Management LLC now owns 50,631 shares of the company’s stock valued at $39,389,000 after acquiring an additional 1,421 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.13% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on LLY. Sanford C. Bernstein began coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective on the stock. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Bank of America dropped their target price on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a report on Thursday, October 31st. Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. Finally, Barclays dropped their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,008.41.

Eli Lilly and Company Stock Down 1.6 %

Eli Lilly and Company stock opened at $818.79 on Wednesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The stock has a fifty day moving average of $893.78 and a 200 day moving average of $870.11. The stock has a market cap of $777.29 billion, a PE ratio of 88.52, a price-to-earnings-growth ratio of 3.15 and a beta of 0.43. Eli Lilly and Company has a one year low of $561.65 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 earnings per share. As a group, sell-side analysts predict that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be paid a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.64%. Eli Lilly and Company’s payout ratio is 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.